Prostate Cancer Testing

Each year, over 50,000 men in the UK are diagnosed with prostate cancer, resulting in more than 12,000 deaths. While it is the most prevalent cancer among men, not all cases are life-threatening. Current diagnostic methods often fail to distinguish between aggressive and indolent forms of the disease. At UEA, we are advancing two innovative diagnostic tools to improve early detection and treatment precision.  

The Prostate Urine Risk (PUR) Test is a non-invasive urine-based test that identifies aggressive prostate cancer without the need for a biopsy, offering a significant improvement over the standard PSA blood test. The DESNT Tiger Test is an AI-powered diagnostic that uses biomarker profiling to differentiate high-risk “tiger” cancers from less harmful types, enabling more targeted treatment decisions and reducing unnecessary interventions. 

In parallel, we are pioneering a novel prevention strategy focused on identifying and targeting cancer-associated bacteria, with the aim of reducing the risk of prostate cancer development. Together, these innovations have the potential to enhance patient outcomes and deliver substantial economic benefits to healthcare systems such as the NHS.